Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Cancer has typically been treated by either radiation, surgery, drugs. In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com Contributor Brian Orelli discuss how the treatments work and the potential data readouts that Novocure will experience in 2021. Corinne Cardina: Any upcoming data readouts that investors should be paying attention to?
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.
NovoCure Ltd. is pulling back Monday and the weakness may not be over. In early November we reviewed the charts of NVCR and wrote that, "If you are still long NVCR from early October then I would continue to hold those positions but raise stop protection to a close below $110 now." In the updated daily Japanese candlestick chart of NVCR, below, we can see some upper shadows last month telling us that traders were rejecting the highs.
Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Novocure announced national reimbursement in Switzerland for Optune in combination with temozolomide for the treatment of newly diagnosed GBM.
Novocure announced the first patient has been enrolled in its global phase 3 TRIDENT trial.